Vectura Group (LON:VEC)‘s stock had its “hold” rating reiterated by stock analysts at Peel Hunt in a research note issued to investors on Wednesday.
Several other equities analysts also recently commented on the company. Citigroup reiterated a “buy” rating and issued a GBX 155 ($2.03) target price on shares of Vectura Group in a research report on Monday, September 10th. Royal Bank of Canada dropped their target price on Vectura Group from GBX 92 ($1.20) to GBX 88 ($1.15) and set a “sector performer” rating for the company in a research report on Wednesday, September 12th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a GBX 140 ($1.83) target price on shares of Vectura Group in a research report on Tuesday, August 21st. Numis Securities reiterated a “buy” rating on shares of Vectura Group in a research report on Wednesday, September 12th. Finally, Shore Capital reiterated a “hold” rating on shares of Vectura Group in a research report on Tuesday, September 11th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of GBX 127.67 ($1.67).
Vectura Group stock opened at GBX 70.45 ($0.92) on Wednesday. Vectura Group has a 12 month low of GBX 70 ($0.91) and a 12 month high of GBX 166.97 ($2.18).
Vectura Group Company Profile
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Featured Story: How dollar cost averaging works
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.